Orchestra BioMed Holdings (OBIO) Enterprise Value (2022 - 2025)
Orchestra BioMed Holdings (OBIO) has disclosed Enterprise Value for 4 consecutive years, with -$53.8 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 43.88% to -$53.8 million in Q3 2025 year-over-year; TTM through Mar 2025 was -$49.9 million, a N/A change, with the full-year FY2024 number at -$66.8 million, up 21.12% from a year prior.
- Enterprise Value was -$53.8 million for Q3 2025 at Orchestra BioMed Holdings, down from -$15.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$23000.0 in Q1 2024 to a low of -$127.1 million in Q1 2023.
- A 4-year average of -$42.7 million and a median of -$23.7 million in 2024 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: soared 99.98% in 2024, then crashed 216786.96% in 2025.
- Orchestra BioMed Holdings' Enterprise Value stood at -$83.7 million in 2022, then dropped by 1.19% to -$84.7 million in 2023, then increased by 21.12% to -$66.8 million in 2024, then increased by 19.46% to -$53.8 million in 2025.
- Per Business Quant, the three most recent readings for OBIO's Enterprise Value are -$53.8 million (Q3 2025), -$15.2 million (Q2 2025), and -$49.9 million (Q1 2025).